



[illegible]

Form PTO-1449		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>			Atty. Docket No. <b>1747/55293-A/ JPW/AJM/MVM</b>		Serial No. <b>09/329,917</b>	
<b>RECEIVED</b> <b>FEB 28 2003</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary) <b>OFFICE OF PETITIONS</b>					Applicant <b>Carlos Cordon-Cardo et al.</b>			
					Filing Date <b>June 10, 1999</b>		Group <b>1634</b>	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<del>Duplicate</del>		<del>WO 9 9 0 4 2 3 8</del>	<del>1/28/99</del>	<del>PCT</del>				
<del>Duplicate</del>		<del>WO 9 8 3 3 4 5 0</del>	<del>5/6/98</del>	<del>PCT</del>				
	<i>JP</i>	WO 9 4 2 2 4 7 8	10/13/94	PCT (Exhibit 1)				
	<i>JP</i>	WO 9 9 3 1 1 4 0	6/24/99	PCT (Exhibit 2)				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	<i>JP</i>	Aaltomaa, S. et al. (1999) "Prognostic Value and Expression of p21 (waf1/cip1) Protein in Prostate Cancer" <i>The Prostate</i> , 39(1):8-15 (Exhibit 3);						
<del>Duplicate</del>		<del>Agus, D.B. et al. (1999) "Response of Prostate Cancer to Anti-HER-2/neu Antibody in Androgen-Dependent and -Independent Human Xenograft Models" <i>Cancer Research</i>, 59(1):4761-4764;</del>						
	<i>JP</i>	Arai, Y. et al. (1997) "C-erbB-2 Oncoprotein: A Potential Biomarker of Advanced Prostate Cancer" <i>Prostate</i> , 30(3):195-201 (Exhibit 4);						
	<i>JP</i>	Baretton, G.B. et al. (1999) "Proliferation- and Apoptosis-Associated Factors in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy: Prognostic Significance of p21/WAF1/CIP1 Expression" <i>British Journal of Cancer</i> , 80(3-4):546-555 (Exhibit 5);						
	<i>JP</i>	Baselga, J. et al., (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts" 58(13):2825-2831 (Exhibit 6);						
EXAMINER		DATE CONSIDERED						
		<i>Jelanne Siffert</i> <i>4/8/04</i>						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.								

Applicants: Carlos Cordon-Cardo et al.  
 Serial No.: 09/329,917  
 Filing Date: June 10, 1999  
 Exhibit A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 1747/55293-A/ JPW/AJM/MVM		Serial No. 09/329,917	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)					Applicant <b>Carlos Cordon-Cardo et al.</b>			
<b>RECEIVED</b>  FEB 28 2003 U.S. PATENT DOCUMENTS OFFICE OF PETITIONS					Filing Date <b>June 10, 1999</b>		Group <b>1634</b>	

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<p>op</p>	Cariou S. et al. (1998) "Prognostic Implication of Expression of the Cell Cycle Inhibitor Protein P27", <i>Breast Cancer Research and Treatment</i> , 1-3(52):29-41 ( <b>Exhibit 7</b> );
<p>Duplicate</p>	Cordon-Cardo Carlos, et al. (1998) "Distinct Altered Patterns of p27 <sup>KIP1</sup> Gene Expression in Benign Prostatic Hyperplasia and Prostatic Carcinoma" <i>J. Natl. Cancer Inst.</i> 90(17): 1284-1291;
<p>Duplicate</p>	Cote, R.J. et al. (1998) "Association of p27 <sup>KIP1</sup> Levels With Recurrence and Survival in Patients With Stage C Prostate Carcinoma" <i>J. Natl. Cancer Inst.</i> 90(12): 916-920;
<p>op</p>	Chen, Y. et al. (1998) "Increased Cell Growth and Tumorigenicity in Human Prostate LNCaP Cells by Overexpression to Cyclin D1" <i>Oncogene</i> , 16(15):1913-1920 ( <b>Exhibit 8</b> );

EXAMINER <i>Jehanne Sittler</i>	DATE CONSIDERED <b>4/8/04</b>
------------------------------------	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1747/55293-A/ JPW/AJM/MVM		Serial No. 09/329,917		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Carlos Cordon-Cardo et al.				
				Filing Date June 10, 1999		Group 1634		
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
9		Craft, N. et al., (1999) "A Mechanism for Hormone-Independent Prostate Cancer Through Modulation of Androgen Receptor Signaling by the HER-2/neu tyrosine Kinase" <i>Nature Medicine</i> , 5(3):280-285 (Exhibit 9);						
9		Curnow, R.T. et al., (1997) "Clinical Experience With CD64-Directed Immunotherapy. An Overview" <i>Cancer Immunology And Immunotherapy</i> , 45(3-4):210-15 (Exhibit 10);						
		Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (1999-03) Lee Tae Yoon et al., "Immunohistochemical Expression of p53 and MDM 2 Protein in Various Epithelial Carcinomas" Database Accession No. PREV1999900406745 (Exhibit 11);						
cate		DeMarzo, A.M. et al. (1998) "Prostate Stem Cell Compartments: Expression of the Cell Cycle Inhibitor, p27kip1 in Normal, Hyperplastic, and Neoplastic Cells" <i>Amer. J. Path.</i> 153(3): 911-919;						
EXAMINER		DATE CONSIDERED						
Gehanne Sittou		4/8/04						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.								

RECEIVED  
FEB 28 2003  
OFFICE OF PETITIONS

RECEIVED  
FEB 28 2003  
OFFICE OF PETITIONS

OFFICE OF PETITIONS

OFFICE OF PETITIONS



